Zimmer Biomet completes acquisition of Paragon 28 for $13.00/share plus CVR

ZIMMER BIOMET HOLDINGS, INC.

Closing on April 21, 2025; each Paragon 28 share converted to $13.00 cash plus up to $1.00 CVR tied to revenue milestones.
Paragon 28 becomes wholly-owned subsidiary; delisted from NYSE effective April 21, 2025.
Deal strengthens Zimmer Biomet's foot and ankle segment, a ~$5B market growing high-single digits.
Leverages Paragon 28's dedicated sales channel to accelerate ASC penetration and global growth.
Transaction expected to accelerate Zimmer Biomet's weighted-average market growth rate (WAMGR).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.